FacebookTweetPin Solid earnings from Microsoft (NASDAQ: MSFT) and Meta Platforms (NASDAQ: META) caused the stock market to ...

Arvinas, along with its partner Pfizer, cancelled plans for a Phase 3 trial combining its PROTAC vepdegestrant with its CDK4 ...

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining over 1.5% on Thursday. Following the market opening Thursday, the Dow traded up 0.51% to 40,876.98 while the NASDAQ climbed ...

Arvinas (NASDAQ:ARVN) stock drops 33% after announcing workforce cuts and trial removals, despite beating earnings ...

Pfizer and Arvinas have axed two phase 3 trials from their estrogen receptor (ER) degrader R&D plan in the wake of mixed data ...

Arvinas, Inc. (NASDAQ:ARVN) shares fell sharply by 29% as the market reacted to the company’s announcement of a significant workforce reduction and the removal of two Phase 3 trials from its ...

Arvinas (ARVN) delivered earnings and revenue surprises of 232.56% and 332.53%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Arvinas is laying off about a third of its workforce, while Entrada is focusing more on Duchenne research. Elsewhere, Biogen talked down tariff impacts and Merck earmarked $1 billion for a biologics ...

On March 31, 2025, Phathom launched a celebrity partnership with Kenan Thompson as part of the GERD IS NO JOKE campaign, marking his first public discussion about living with GERD and finding relief ...

Reported positive topline results from the Phase 3 VERITAC-2 trial that support global regulatory filings – – Presented first ...

Arvinas (NASDAQ:ARVN) is scheduled to announce Q1 earnings results on Thursday, May 1st, before market open. The consensus ...